Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remdesivir + abiraterone acetate + prednisolone
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Veklury + abiraterone acetate + prednisolone is an artificial drug combination that does not exist as a standard therapeutic regimen or commercial product. The combination of these three agents—remdesivir (Veklury, an antiviral RNA polymerase inhibitor), abiraterone acetate (an androgen synthesis inhibitor), and prednisolone (a corticosteroid)—primarily appears in public documents due to PDF table parsing errors. Specifically, in NHS formulary documents, the entry for Veklury (SMC2550) has been erroneously merged with the oncology indication for olaparib (Lynparza) or abiraterone acetate in combination with prednisone/prednisolone. In clinical practice, these drugs would only be co-administered if a prostate cancer patient undergoing treatment with abiraterone acetate and prednisolone subsequently contracted COVID-19 and required remdesivir therapy.
- Other names
- remdesivir + abiraterone acetate + prednisoloneVeklury + abiraterone acetate + prednisolone
02
Targets
AR (Adrenergic receptors)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on remdesivir + abiraterone acetate + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remdesivir + abiraterone acetate + prednisolone.